NanoViricides, Inc.
0.5M
$22.87M
-2.24
$-0.63
No price alerts set. Add an alert to get notified!
-2.24
2.82
$-0.63
-125.93%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ANTX
AN2 Therapeutics, Inc.
|
$3.62 | 0.00% | -3.11 | $99.20M | 0.00 |
|
EVAX
Evaxion Biotech A/S
|
$4.49 | 0.00% | -3.72 | $28.36M | 0.44 |
|
GBIO
Generation Bio Co.
|
$5.34 | 0.00 | -0.57 | $35.98M | 0.52 |
|
IGC
IGC Pharma, Inc.
|
$0.32 | -5.03% | -5.67 | $31.52M | 0.02 |
|
JSPR
Jasper Therapeutics, Inc.
|
$1.06 | 3.92% | -0.27 | $17.23M | 0.30 |
|
MAIA
MAIA Biotechnology, Inc.
|
$1.41 | 4.44% | -2.02 | $54.51M | 0.00 |
|
QTTB
Q32 Bio Inc.
|
$6.65 | 13.68% | 2.80 | $81.79M | 0.27 |
|
SABS
SAB Biotherapeutics, Inc.
|
$3.86 | 0.26% | 5.62 | $36.89M | 0.04 |
|
TENX
Tenax Therapeutics, Inc.
|
$14.10 | -2.42% | -10.51 | $242.49M | 0.00 |
|
VRCA
Verrica Pharmaceuticals Inc.
|
$6.38 | 0.95% | -3.80 | $67.96M | 0.07 |
* Peer stocks are selected based on market capitalization and sector
$2.23
$0.85
$0.00
0.00%
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
